{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T14:28:44Z","timestamp":1794666524889,"version":"4.9.1"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T00:00:00Z","timestamp":1743724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T00:00:00Z","timestamp":1743724800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur Radiol"],"abstract":"<jats:sec>\n            <jats:title>Abstract<\/jats:title>\n            <jats:p>The presence of histologically defined prostate cancer (PCa) is common and rises with age. Nevertheless, histological evidence of PCa does not always lead to clinically evident or life-threatening disease, and we know that PSA-based population screening can find twice the prevalence of PCa than would present via clinical routes. The PROTECT study randomized men diagnosed through PSA screening, to surgery, radiotherapy, or active monitoring. At 15 years, PCa-related deaths ranged from 2.1% in the surgery group to 2.9% in the active monitoring group, while the risk of death from other causes was 22%. Modern PCa diagnosis uses MRI to determine who needs a biopsy and how it is done.<\/jats:p>\n            <jats:p>Multiparametric MRI can selectively detect PCa of higher grade and volume, which is more likely to be associated with progression, metastases, and death, and hence to benefit from treatment. MRI and MRI-targeted biopsies are recommended prior to enrolment in active surveillance (AS) programs for accurate risk classification. The UCLH AS cohort based on per-cause MRI evaluations has shown baseline Gleason grade and MRI index lesion visibility to be strong predictors of progression to treatment. Serial evaluation with MRI has been codified with the PRECISE recommendations to support MRI-based monitoring during AS.<\/jats:p>\n            <jats:p>AS recommendations have extended to certain favorable-intermediate risk cancers. The Movember International Consensus Meeting has determined a dynamic risk-stratified AS approach to be the highest-ranked research priority.<\/jats:p>\n            <jats:p>We review the impact of MRI on AS from patient selection to risk stratification, and the development of MRI-led personalized AS protocols.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Key Points<\/jats:title>\n            <jats:p>\n              <jats:bold>\n                <jats:italic>Question<\/jats:italic>\n              <\/jats:bold>\n              <jats:italic>Standardized protocols are not able to address the heterogeneity of men on active surveillance for PCa and are burdened by unnecessary examinations<\/jats:italic>.<\/jats:p>\n            <jats:p>\n              <jats:bold>\n                <jats:italic>Findings<\/jats:italic>\n              <\/jats:bold>\n              <jats:italic>MRI can improve the selection of men for active surveillance, predict time to treatment, and risk-stratify patients at risk of progression<\/jats:italic>.<\/jats:p>\n            <jats:p>\n              <jats:bold>\n                <jats:italic>Clinical relevance<\/jats:italic>\n              <\/jats:bold>\n              <jats:italic>MRI-led risk-adapted protocols may reduce the burden of active surveillance on patients, improve adherence, and reduce healthcare costs<\/jats:italic>.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s00330-025-11518-z","type":"journal-article","created":{"date-parts":[[2025,4,5]],"date-time":"2025-04-05T16:39:23Z","timestamp":1743871163000},"page":"6444-6453","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Personalized risk-adapted models in prostate cancer during active surveillance using MRI\u2014a narrative review"],"prefix":"10.1007","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5012-7219","authenticated-orcid":false,"given":"Davide","family":"Maffei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline M.","family":"Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,4]]},"reference":[{"key":"11518_CR1","first-page":"497","volume":"29","author":"RS Ferguson","year":"1933","unstructured":"Ferguson RS (1933) Recent advances in the diagnosis of carcinoma of the prostate. Can Med Assoc J 29:497\u2013501","journal-title":"Can Med Assoc J"},{"key":"11518_CR2","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/S0022-5347(17)63039-8","volume":"97","author":"GT Mellinger","year":"1967","unstructured":"Mellinger GT, Gleason D, Bailar J (1967) The histology and prognosis of prostatic cancer. J Urol 97:331\u2013337. https:\/\/doi.org\/10.1016\/S0022-5347(17)63039-8","journal-title":"J Urol"},{"key":"11518_CR3","doi-asserted-by":"publisher","first-page":"e87","DOI":"10.1097\/PAS.0000000000001497","volume":"44","author":"GJLH van Leenders","year":"2020","unstructured":"van Leenders GJLH, van der Kwast TH, Grignon DJ et al (2020) The 2019 International Society of Urological Pathology (ISUP) consensus conference on grading of prostatic carcinoma. Am J Surg Pathol 44:e87. https:\/\/doi.org\/10.1097\/PAS.0000000000001497","journal-title":"Am J Surg Pathol"},{"key":"11518_CR4","doi-asserted-by":"publisher","first-page":"4294","DOI":"10.1200\/JCO.2012.44.0586","volume":"30","author":"HB Carter","year":"2012","unstructured":"Carter HB, Partin AW, Walsh PC et al (2012) Gleason score 6 adenocarcinoma: Should it be labeled as cancer? J Clin Oncol 30:4294\u20134296. https:\/\/doi.org\/10.1200\/JCO.2012.44.0586","journal-title":"J Clin Oncol"},{"key":"11518_CR5","doi-asserted-by":"publisher","first-page":"288","DOI":"10.3322\/canjclin.47.5.288","volume":"47","author":"ED Crawford","year":"1997","unstructured":"Crawford ED (1997) Prostate cancer awareness week: September 22 to 28. CA Cancer J Clin 47:288\u2013296. https:\/\/doi.org\/10.3322\/canjclin.47.5.288","journal-title":"CA Cancer J Clin"},{"key":"11518_CR6","first-page":"159","volume":"17","author":"MC Wang","year":"1979","unstructured":"Wang MC, Valenzuela LA, Murphy GP, Chu TM (1979) Purification of a human prostate specific antigen. Invest Urol 17:159\u2013163","journal-title":"Invest Urol"},{"key":"11518_CR7","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1001\/jama.280.11.975","volume":"280","author":"PC Albertsen","year":"1998","unstructured":"Albertsen PC, Hanley JA, Gleason DF, Barry MJ (1998) Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer. JAMA 280:975\u2013980. https:\/\/doi.org\/10.1001\/jama.280.11.975","journal-title":"JAMA"},{"key":"11518_CR8","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1056\/NEJMoa2214122","volume":"388","author":"FC Hamdy","year":"2023","unstructured":"Hamdy FC, Donovan JL, Lane JA et al (2023) Fifteen-year outcomes after monitoring, surgery, or radiotherapy for prostate cancer. N Engl J Med 388:1547\u20131558. https:\/\/doi.org\/10.1056\/NEJMoa2214122","journal-title":"N Engl J Med"},{"key":"11518_CR9","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1016\/s0022-5347(17)41178-5","volume":"141","author":"JN Kabalin","year":"1989","unstructured":"Kabalin JN, McNeal JE, Price HM et al (1989) Unsuspected adenocarcinoma of the prostate in patients undergoing cystoprostatectomy for other causes: incidence, histology and morphometric observations. J Urol 141:1091\u20131094. https:\/\/doi.org\/10.1016\/s0022-5347(17)41178-5. discussion 1093-1094","journal-title":"J Urol"},{"key":"11518_CR10","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1016\/s0022-5347(17)32370-4","volume":"152","author":"JI Epstein","year":"1994","unstructured":"Epstein JI, Walsh PC, Brendler CB (1994) Radical prostatectomy for impalpable prostate cancer: the Johns Hopkins experience with tumors found on transurethral resection (stages T1A and T1B) and on needle biopsy (stage T1C). J Urol 152:1721\u20131729. https:\/\/doi.org\/10.1016\/s0022-5347(17)32370-4","journal-title":"J Urol"},{"key":"11518_CR11","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1111\/j.1464-410X.2006.06660.x","volume":"99","author":"MH Winkler","year":"2007","unstructured":"Winkler MH, Livni N, Mannion EM et al (2007) Characteristics of incidental prostatic adenocarcinoma in contemporary radical cystoprostatectomy specimens. BJU Int 99:554\u2013558. https:\/\/doi.org\/10.1111\/j.1464-410X.2006.06660.x","journal-title":"BJU Int"},{"key":"11518_CR12","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.juro.2010.08.082","volume":"185","author":"T Wolters","year":"2011","unstructured":"Wolters T, Roobol MJ, van Leeuwen PJ et al (2011) A critical analysis of the tumor volume threshold for clinically insignificant prostate cancer using a data set of a randomized screening trial. J Urol 185:121\u2013125. https:\/\/doi.org\/10.1016\/j.juro.2010.08.082","journal-title":"J Urol"},{"key":"11518_CR13","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1016\/S0140-6736(16)32401-1","volume":"389","author":"HU Ahmed","year":"2017","unstructured":"Ahmed HU, El-Shater Bosaily A, Brown LC et al (2017) Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study. Lancet 389:815\u2013822. https:\/\/doi.org\/10.1016\/S0140-6736(16)32401-1","journal-title":"Lancet"},{"key":"11518_CR14","doi-asserted-by":"publisher","first-page":"1644","DOI":"10.1007\/s00330-020-07256-z","volume":"31","author":"F Giganti","year":"2021","unstructured":"Giganti F, Stabile A, Stavrinides V et al (2021) Natural history of prostate cancer on active surveillance: stratification by MRI using the PRECISE recommendations in a UK cohort. Eur Radiol 31:1644\u20131655. https:\/\/doi.org\/10.1007\/s00330-020-07256-z","journal-title":"Eur Radiol"},{"key":"11518_CR15","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1056\/NEJMoa1801993","volume":"378","author":"V Kasivisvanathan","year":"2018","unstructured":"Kasivisvanathan V, Rannikko AS, Borghi M et al (2018) MRI-targeted or standard biopsy for prostate-cancer diagnosis. N Engl J Med 378:1767\u20131777. https:\/\/doi.org\/10.1056\/NEJMoa1801993","journal-title":"N Engl J Med"},{"key":"11518_CR16","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1097\/JU.0000000000001474","volume":"205","author":"AG Wibmer","year":"2021","unstructured":"Wibmer AG, Chaim J, Lakhman Y et al (2021) Oncologic outcomes after localized prostate cancer treatment: associations with pretreatment prostate magnetic resonance imaging findings. J Urol 205:1055\u20131062. https:\/\/doi.org\/10.1097\/JU.0000000000001474","journal-title":"J Urol"},{"key":"11518_CR17","doi-asserted-by":"publisher","first-page":"2084","DOI":"10.1001\/jama.2024.6695","volume":"331","author":"LF Newcomb","year":"2024","unstructured":"Newcomb LF, Schenk JM, Zheng Y et al (2024) Long-term outcomes in patients using protocol-directed active surveillance for prostate cancer. JAMA 331:2084\u20132093. https:\/\/doi.org\/10.1001\/jama.2024.6695","journal-title":"JAMA"},{"key":"11518_CR18","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1093\/tbm\/ibx005","volume":"8","author":"KL Taylor","year":"2018","unstructured":"Taylor KL, Luta G, Hoffman RM et al (2018) Quality of life among men with low-risk prostate cancer during the first year following diagnosis: the PREPARE prospective cohort study. Transl Behav Med 8:156\u2013165. https:\/\/doi.org\/10.1093\/tbm\/ibx005","journal-title":"Transl Behav Med"},{"key":"11518_CR19","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1038\/pcan.2015.38","volume":"18","author":"I Cook","year":"2015","unstructured":"Cook I, Angel JB, Vera PL et al (2015) Rectal swab testing before prostate biopsy: experience in a VA Medical Center urology practice. Prostate Cancer Prostatic Dis 18:365\u2013369. https:\/\/doi.org\/10.1038\/pcan.2015.38","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"11518_CR20","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.eururo.2023.12.015","volume":"86","author":"JC Hu","year":"2024","unstructured":"Hu JC, Assel M, Allaf ME et al (2024) Transperineal versus transrectal magnetic resonance imaging\u2013targeted and systematic prostate biopsy to prevent infectious complications: the PREVENT randomized trial. Eur Urol 86:61\u201368. https:\/\/doi.org\/10.1016\/j.eururo.2023.12.015","journal-title":"Eur Urol"},{"key":"11518_CR21","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1016\/j.eururo.2018.10.025","volume":"75","author":"M Van Hemelrijck","year":"2019","unstructured":"Van Hemelrijck M, Ji X, Helleman J et al (2019) Reasons for discontinuing active surveillance: assessment of 21 centres in 12 countries in the movember GAP3 consortium. Eur Urol 75:523\u2013531. https:\/\/doi.org\/10.1016\/j.eururo.2018.10.025","journal-title":"Eur Urol"},{"key":"11518_CR22","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1002\/pros.24330","volume":"82","author":"KR Beckmann","year":"2022","unstructured":"Beckmann KR, Bangma CH, Helleman J et al (2022) Comparison of outcomes of different biopsy schedules among men on active surveillance for prostate cancer: an analysis of the G.A.P.3 global consortium database. Prostate 82:876\u2013879. https:\/\/doi.org\/10.1002\/pros.24330","journal-title":"Prostate"},{"key":"11518_CR23","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1111\/bju.15136","volume":"127","author":"A Tomer","year":"2020","unstructured":"Tomer A, Nieboer D, Roobol MJ et al (2020) Personalised biopsy schedules based on risk of Gleason upgrading for patients with low-risk prostate cancer on active surveillance. BJU Int 127:96. https:\/\/doi.org\/10.1111\/bju.15136","journal-title":"BJU Int"},{"key":"11518_CR24","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1016\/j.juro.2012.04.107","volume":"188","author":"WE Barzell","year":"2012","unstructured":"Barzell WE, Melamed MR, Cathcart P et al (2012) Identifying candidates for active surveillance: an evaluation of the repeat biopsy strategy for men with favorable risk prostate cancer. J Urol 188:762\u2013767. https:\/\/doi.org\/10.1016\/j.juro.2012.04.107","journal-title":"J Urol"},{"key":"11518_CR25","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1111\/j.1464-410X.2009.08938.x","volume":"105","author":"N Lawrentschuk","year":"2010","unstructured":"Lawrentschuk N, Haider MA, Daljeet N et al (2010) Prostatic evasive anterior tumours': the role of magnetic resonance imaging. BJU Int 105:1231\u20131236. https:\/\/doi.org\/10.1111\/j.1464-410X.2009.08938.x","journal-title":"BJU Int"},{"key":"11518_CR26","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1097\/RLI.0000000000000157","volume":"50","author":"EK Vos","year":"2015","unstructured":"Vos EK, Kobus T, Litjens GJS et al (2015) Multiparametric magnetic resonance imaging for discriminating low-grade from high-grade prostate cancer. Invest Radiol 50:490\u2013497. https:\/\/doi.org\/10.1097\/RLI.0000000000000157","journal-title":"Invest Radiol"},{"key":"11518_CR27","doi-asserted-by":"publisher","first-page":"2019","DOI":"10.1007\/s00330-013-2795-0","volume":"23","author":"F Bratan","year":"2013","unstructured":"Bratan F, Niaf E, Melodelima C et al (2013) Influence of imaging and histological factors on prostate cancer detection and localisation on multiparametric MRI: a prospective study. Eur Radiol 23:2019\u20132029. https:\/\/doi.org\/10.1007\/s00330-013-2795-0","journal-title":"Eur Radiol"},{"key":"11518_CR28","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/j.eururo.2014.08.079","volume":"67","author":"JD Le","year":"2015","unstructured":"Le JD, Tan N, Shkolyar E et al (2015) Multifocality and prostate cancer detection by multiparametric magnetic resonance imaging: correlation with whole-mount histopathology. Eur Urol 67:569\u2013576. https:\/\/doi.org\/10.1016\/j.eururo.2014.08.079","journal-title":"Eur Urol"},{"key":"11518_CR29","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.euf.2019.03.001","volume":"7","author":"S Dieffenbacher","year":"2021","unstructured":"Dieffenbacher S, Nyarangi-Dix J, Giganti F et al (2021) Standardized magnetic resonance imaging reporting using the prostate cancer radiological estimation of change in sequential evaluation criteria and magnetic resonance imaging\/transrectal ultrasound fusion with transperineal saturation biopsy to select men on active surveillance. Eur Urol Focus 7:102\u2013110. https:\/\/doi.org\/10.1016\/j.euf.2019.03.001","journal-title":"Eur Urol Focus"},{"key":"11518_CR30","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/j.eururo.2018.06.025","volume":"75","author":"L Klotz","year":"2019","unstructured":"Klotz L, Loblaw A, Sugar L et al (2019) Active surveillance magnetic resonance imaging study (ASIST): results of a randomized multicenter prospective trial. Eur Urol 75:300\u2013309. https:\/\/doi.org\/10.1016\/j.eururo.2018.06.025","journal-title":"Eur Urol"},{"key":"11518_CR31","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.eururo.2019.10.007","volume":"77","author":"L Klotz","year":"2020","unstructured":"Klotz L, Pond G, Loblaw A et al (2020) Randomized study of systematic biopsy versus magnetic resonance imaging and targeted and systematic biopsy in men on active surveillance (ASIST): 2-year postbiopsy follow-up. Eur Urol 77:311\u2013317. https:\/\/doi.org\/10.1016\/j.eururo.2019.10.007","journal-title":"Eur Urol"},{"key":"11518_CR32","doi-asserted-by":"publisher","first-page":"7068","DOI":"10.1007\/s00330-024-10795-4","volume":"34","author":"M de Rooij","year":"2024","unstructured":"de Rooij M, Allen C, Twilt JJ et al (2024) PI-QUAL version 2: an update of a standardised scoring system for the assessment of image quality of prostate MRI. Eur Radiol 34:7068\u20137079. https:\/\/doi.org\/10.1007\/s00330-024-10795-4","journal-title":"Eur Radiol"},{"key":"11518_CR33","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1016\/j.eururo.2019.02.033","volume":"76","author":"B Turkbey","year":"2019","unstructured":"Turkbey B, Rosenkrantz AB, Haider MA et al (2019) Prostate imaging reporting and data system version 2.1: 2019 update of prostate imaging reporting and data system version 2. Eur Urol 76:340\u2013351. https:\/\/doi.org\/10.1016\/j.eururo.2019.02.033","journal-title":"Eur Urol"},{"key":"11518_CR34","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1111\/bju.16287","volume":"133","author":"L Lenfant","year":"2024","unstructured":"Lenfant L, Beitone C, Troccaz J et al (2024) Learning curve for fusion magnetic resonance imaging targeted prostate biopsy and three-dimensional transrectal ultrasonography segmentation. BJU Int 133:709\u2013716. https:\/\/doi.org\/10.1111\/bju.16287","journal-title":"BJU Int"},{"key":"11518_CR35","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s13244-023-01574-8","volume":"15","author":"T Barrett","year":"2024","unstructured":"Barrett T, Lee K-L, Illerstam F et al (2024) Interactive training workshop to improve prostate mpMRI knowledge: results from the ESOR Nicholas Gourtsoyiannis teaching fellowship. Insights Imaging 15:27. https:\/\/doi.org\/10.1186\/s13244-023-01574-8","journal-title":"Insights Imaging"},{"key":"11518_CR36","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1111\/bju.12892","volume":"117","author":"G Gaziev","year":"2016","unstructured":"Gaziev G, Wadhwa K, Barrett T et al (2016) Defining the learning curve for multiparametric magnetic resonance imaging (MRI) of the prostate using MRI -transrectal ultrasonography (TRUS) fusion-guided transperineal prostate biopsies as a validation tool. BJU Int 117:80\u201386. https:\/\/doi.org\/10.1111\/bju.12892","journal-title":"BJU Int"},{"key":"11518_CR37","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1097\/PAS.0000000000000235","volume":"38","author":"CC Huang","year":"2014","unstructured":"Huang CC, Kong MX, Zhou M et al (2014) Gleason score 3\u2009+\u20094\u2009=\u20097 prostate cancer with minimal quantity of gleason pattern 4 on needle biopsy is associated with low-risk tumor in radical prostatectomy specimen. Am J Surg Pathol 38:1096\u20131101. https:\/\/doi.org\/10.1097\/PAS.0000000000000235","journal-title":"Am J Surg Pathol"},{"key":"11518_CR38","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.euo.2023.01.003","volume":"6","author":"CM Moore","year":"2023","unstructured":"Moore CM, King LE, Withington J et al (2023) Best current practice and research priorities in active surveillance for prostate cancer\u2014a report of a movember international consensus meeting. Eur Urol Oncol 6:160\u2013182. https:\/\/doi.org\/10.1016\/j.euo.2023.01.003","journal-title":"Eur Urol Oncol"},{"key":"11518_CR39","doi-asserted-by":"publisher","first-page":"e1002063","DOI":"10.1371\/journal.pmed.1002063","volume":"13","author":"VJ Gnanapragasam","year":"2016","unstructured":"Gnanapragasam VJ, Lophatananon A, Wright KA et al (2016) Improving clinical risk stratification at diagnosis in primary prostate cancer: a prognostic modelling study. PLoS Med 13:e1002063. https:\/\/doi.org\/10.1371\/journal.pmed.1002063","journal-title":"PLoS Med"},{"key":"11518_CR40","unstructured":"NICE Guidance (2019) Prostate cancer: diagnosis and management. https:\/\/www.nice.org.uk\/guidance\/ng131. Accessed 22 Aug 2024"},{"key":"11518_CR41","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1038\/s41746-022-00659-w","volume":"5","author":"C Lee","year":"2022","unstructured":"Lee C, Light A, Saveliev ES et al (2022) Developing machine learning algorithms for dynamic estimation of progression during active surveillance for prostate cancer. NPJ Digit Med 5:110. https:\/\/doi.org\/10.1038\/s41746-022-00659-w","journal-title":"NPJ Digit Med"},{"key":"11518_CR42","doi-asserted-by":"publisher","first-page":"e203187","DOI":"10.1001\/jamaoncol.2020.3187","volume":"6","author":"MR Cooperberg","year":"2020","unstructured":"Cooperberg MR, Zheng Y, Faino AV et al (2020) Tailoring intensity of active surveillance for low-risk prostate cancer based on individualized prediction of risk stability. JAMA Oncol 6:e203187. https:\/\/doi.org\/10.1001\/jamaoncol.2020.3187","journal-title":"JAMA Oncol"},{"key":"11518_CR43","doi-asserted-by":"publisher","first-page":"216","DOI":"10.3390\/jcm12010216","volume":"12","author":"A Light","year":"2022","unstructured":"Light A, Lophatananon A, Keates A et al (2022) Development and external validation of the stratified cancer surveillance (STRATCANS) multivariable model for predicting progression in men with newly diagnosed prostate cancer starting active surveillance. J Clin Med 12:216. https:\/\/doi.org\/10.3390\/jcm12010216","journal-title":"J Clin Med"},{"key":"11518_CR44","doi-asserted-by":"publisher","first-page":"132","DOI":"10.21037\/tau.2017.12.29","volume":"7","author":"IG Schoots","year":"2018","unstructured":"Schoots IG, Osses DF, Drost F-JH et al (2018) Reduction of MRI-targeted biopsies in men with low-risk prostate cancer on active surveillance by stratifying to PI-RADS and PSA-density, with different thresholds for significant disease. Transl Androl Urol 7:132\u2013144. https:\/\/doi.org\/10.21037\/tau.2017.12.29","journal-title":"Transl Androl Urol"},{"key":"11518_CR45","doi-asserted-by":"publisher","unstructured":"Bhanji Y, Mamawala MK, Fletcher SA et al (2024) Is confirmatory biopsy still necessary for active surveillance of men with grade Group 1 prostate cancer in the era of multiparametric MRI? J Urol. https:\/\/doi.org\/10.1097\/JU.0000000000004268","DOI":"10.1097\/JU.0000000000004268"},{"key":"11518_CR46","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.eururo.2024.03.027","volume":"86","author":"P Cornford","year":"2024","unstructured":"Cornford P, van den Bergh RCN, Briers E et al (2024) EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate cancer-2024 update. part I: screening, diagnosis, and local treatment with curative intent. Eur Urol 86:148\u2013163. https:\/\/doi.org\/10.1016\/j.eururo.2024.03.027","journal-title":"Eur Urol"},{"key":"11518_CR47","doi-asserted-by":"publisher","unstructured":"Dias AB, Woo S, Leni R et al (2024) Is MRI ready to replace biopsy during active surveillance? Eur Radiol. https:\/\/doi.org\/10.1007\/s00330-024-10863-9","DOI":"10.1007\/s00330-024-10863-9"},{"key":"11518_CR48","doi-asserted-by":"publisher","unstructured":"van den Bergh RCN, Schoots IG, Cornford PA, European Association of Urology Prostate Cancer Guidelines Panel (2024) Standard repeat biopsies during active surveillance for prostate cancer: Are they necessary in the magnetic resonance imaging era? Eur Urol. https:\/\/doi.org\/10.1016\/j.eururo.2024.09.014","DOI":"10.1016\/j.eururo.2024.09.014"},{"key":"11518_CR49","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/j.eururo.2020.03.035","volume":"78","author":"V Stavrinides","year":"2020","unstructured":"Stavrinides V, Giganti F, Trock B et al (2020) Five-year outcomes of magnetic resonance imaging-based active surveillance for prostate cancer: a large cohort study. Eur Urol 78:443\u2013451. https:\/\/doi.org\/10.1016\/j.eururo.2020.03.035","journal-title":"Eur Urol"},{"key":"11518_CR50","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.eururo.2024.03.014","volume":"86","author":"C Englman","year":"2024","unstructured":"Englman C, Maffei D, Allen C et al (2024) PRECISE version 2: updated recommendations for reporting prostate magnetic resonance imaging in patients on active surveillance for prostate cancer. Eur Urol 86:240\u2013255. https:\/\/doi.org\/10.1016\/j.eururo.2024.03.014","journal-title":"Eur Urol"},{"key":"11518_CR51","doi-asserted-by":"publisher","first-page":"6217","DOI":"10.1007\/s00330-024-10770-z","volume":"34","author":"I Caglic","year":"2024","unstructured":"Caglic I, Sushentsev N, Syer T et al (2024) Biparametric MRI in prostate cancer during active surveillance: Is it safe? Eur Radiol 34:6217\u20136226. https:\/\/doi.org\/10.1007\/s00330-024-10770-z","journal-title":"Eur Radiol"},{"key":"11518_CR52","doi-asserted-by":"publisher","first-page":"3","DOI":"10.2214\/AJR.20.24268","volume":"216","author":"IG Schoots","year":"2021","unstructured":"Schoots IG, Barentsz JO, Bittencourt LK et al (2021) PI-RADS committee position on MRI without contrast medium in biopsy-naive men with suspected prostate cancer: narrative review. AJR Am J Roentgenol 216:3\u201319. https:\/\/doi.org\/10.2214\/AJR.20.24268","journal-title":"AJR Am J Roentgenol"},{"key":"11518_CR53","doi-asserted-by":"crossref","unstructured":"Bozgo V, Roest C, van Oort I et al (2024) Prostate MRI and artificial intelligence during active surveillance: Should we jump on the bandwagon? Eur Radiol 34:7698\u201377040","DOI":"10.1007\/s00330-024-10869-3"},{"key":"11518_CR54","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.euros.2022.12.013","volume":"49","author":"V Thankapannair","year":"2023","unstructured":"Thankapannair V, Keates A, Barrett T, Gnanapragasam VJ (2023) Prospective implementation and early outcomes of a risk-stratified prostate cancer active surveillance follow-up protocol. Eur Urol Open Sci 49:15\u201322. https:\/\/doi.org\/10.1016\/j.euros.2022.12.013","journal-title":"Eur Urol Open Sci"}],"container-title":["European Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00330-025-11518-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00330-025-11518-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00330-025-11518-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T10:09:00Z","timestamp":1757498940000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00330-025-11518-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,4]]},"references-count":54,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025,10]]}},"alternative-id":["11518"],"URL":"https:\/\/doi.org\/10.1007\/s00330-025-11518-z","relation":{},"ISSN":["1432-1084"],"issn-type":[{"value":"1432-1084","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,4]]},"assertion":[{"value":"31 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 January 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 April 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The scientific guarantor of this publication is Caroline M. Moore.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Guarantor"}},{"value":"The authors of this manuscript declare no relationships with any companies, whose products or services may be related to the subject matter of the article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"No complex statistical methods were necessary for this paper.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Statistics and biometry"}},{"value":"Written informed consent was not required.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"Institutional Review Board approval was not required.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Study subjects or cohorts overlap"}},{"order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Methodology"}}]}}